These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 23235148)

  • 101. TDP-43 condensation properties specify its RNA-binding and regulatory repertoire.
    Hallegger M; Chakrabarti AM; Lee FCY; Lee BL; Amalietti AG; Odeh HM; Copley KE; Rubien JD; Portz B; Kuret K; Huppertz I; Rau F; Patani R; Fawzi NL; Shorter J; Luscombe NM; Ule J
    Cell; 2021 Sep; 184(18):4680-4696.e22. PubMed ID: 34380047
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Hyperphosphorylation tunes TDP-43 solubility.
    Ginell GM; Holehouse AS
    EMBO J; 2022 Apr; 41(8):e111062. PubMed ID: 35307855
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life.
    Austin JA; Wright GS; Watanabe S; Grossmann JG; Antonyuk SV; Yamanaka K; Hasnain SS
    Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4309-14. PubMed ID: 24591609
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains.
    Kametani F; Obi T; Shishido T; Akatsu H; Murayama S; Saito Y; Yoshida M; Hasegawa M
    Sci Rep; 2016 Mar; 6():23281. PubMed ID: 26980269
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDa C-terminal fragment of TDP-43.
    Caccamo A; Shaw DM; Guarino F; Messina A; Walker AW; Oddo S
    Hum Mol Genet; 2015 Aug; 24(16):4625-35. PubMed ID: 26002100
    [TBL] [Abstract][Full Text] [Related]  

  • 106. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets.
    Scotter EL; Chen HJ; Shaw CE
    Neurotherapeutics; 2015 Apr; 12(2):352-63. PubMed ID: 25652699
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models.
    Barmada SJ; Serio A; Arjun A; Bilican B; Daub A; Ando DM; Tsvetkov A; Pleiss M; Li X; Peisach D; Shaw C; Chandran S; Finkbeiner S
    Nat Chem Biol; 2014 Aug; 10(8):677-85. PubMed ID: 24974230
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.
    Rosen DR; Siddique T; Patterson D; Figlewicz DA; Sapp P; Hentati A; Donaldson D; Goto J; O'Regan JP; Deng HX
    Nature; 1993 Mar; 362(6415):59-62. PubMed ID: 8446170
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Functional Significance of TDP-43 Mutations in Disease.
    Buratti E
    Adv Genet; 2015; 91():1-53. PubMed ID: 26410029
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Aberrant protein aggregation in amyotrophic lateral sclerosis.
    Wang H; Zeng R
    J Neurol; 2024 Aug; 271(8):4826-4851. PubMed ID: 38869826
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Proteasome localization and activity in pig brain and
    Amrein Almira A; Chen MW; El Demerdash N; Javdan C; Park D; Lee JK; Martin LJ
    Front Cell Neurosci; 2024; 18():1353542. PubMed ID: 38469354
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Monomerization of TDP-43 is a key determinant for inducing TDP-43 pathology in amyotrophic lateral sclerosis.
    Oiwa K; Watanabe S; Onodera K; Iguchi Y; Kinoshita Y; Komine O; Sobue A; Okada Y; Katsuno M; Yamanaka K
    Sci Adv; 2023 Aug; 9(31):eadf6895. PubMed ID: 37540751
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Specific vulnerability of iPSC-derived motor neurons with TDP-43 gene mutation to oxidative stress.
    Onda-Ohto A; Hasegawa-Ogawa M; Matsuno H; Shiraishi T; Bono K; Hiraki H; Kanegae Y; Iguchi Y; Okano HJ
    Mol Brain; 2023 Jul; 16(1):62. PubMed ID: 37496071
    [TBL] [Abstract][Full Text] [Related]  

  • 114. A Novel Drosophila-based Drug Repurposing Platform Identified Fingolimod As a Potential Therapeutic for TDP-43 Proteinopathy.
    Lo Piccolo L; Umegawachi T; Yeewa R; Potikanond S; Nimlamool W; Prachayasittikul V; Gotoh Y; Yoshida H; Yamaguchi M; Jantrapirom S
    Neurotherapeutics; 2023 Sep; 20(5):1330-1346. PubMed ID: 37493896
    [TBL] [Abstract][Full Text] [Related]  

  • 115. ALS-linked TDP-43 mutations interfere with the recruitment of RNA recognition motifs to G-quadruplex RNA.
    Ishiguro A; Ishihama A
    Sci Rep; 2023 Apr; 13(1):5982. PubMed ID: 37046025
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Therapeutic Effect of Rapamycin on TDP-43-Related Pathogenesis in Ischemic Stroke.
    Tsou YS; Lai JH; Chen KY; Chang CF; Huang CC
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614118
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD.
    Tamaki Y; Urushitani M
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293362
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Mitochondrial and Endoplasmic Reticulum Alterations in a Case of Amyotrophic Lateral Sclerosis Caused by TDP-43 A382T Mutation.
    Zanini G; Selleri V; Nasi M; De Gaetano A; Martinelli I; Gianferrari G; Lofaro FD; Boraldi F; Mandrioli J; Pinti M
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233180
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Functional implication of ubiquitinating and deubiquitinating mechanisms in TDP-43 proteinopathies.
    Tran NN; Lee BH
    Front Cell Dev Biol; 2022; 10():931968. PubMed ID: 36158183
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Profiling morphologic MRI features of motor neuron disease caused by
    Spinelli EG; Ghirelli A; Riva N; Canu E; Castelnovo V; Domi T; Pozzi L; Carrera P; Silani V; Chiò A; Filippi M; Agosta F
    Front Neurol; 2022; 13():931006. PubMed ID: 35911889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.